• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

A not-for-profit health and tax policy research organization.

  • Home
  • About Us
    • Mission and History
    • Officers and Trustees
    • Scholars and Staff
    • Who was Galen?
  • Activities
    • Core Activities
    • State Leaders Calls
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Donate
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Prescription Drugs

Trump’s Misguided Solution to Drug Prices

POSTED BY RealClear Health on December 2, 2018.

The Trump administration has made important progress in loosening the federal government’s grip on private health insurance, freeing up more options for affordable health insurance. But the administration has veered off this free-market track with its  recent proposal to, among other things, slap a form of imported price controls on a specific class of prescription drugs in Medicare. To its … [Read more...] about Trump’s Misguided Solution to Drug Prices

Filed Under: Prescription Drugs

Amgen Announces Major Price Cut For Its Breakthrough Cholesterol Drug

POSTED BY Forbes on October 24, 2018.

By Grace-Marie Turner— The Trump administration continues to work overtime to lower prescription drug costs for consumers.  In response, some pharmaceutical companies have announced rollbacks of price increases, cuts in prices, price freezes, or other ways to improve affordability for patients. In the latest example, Amgen, a leading biologics company, is stepping forward to bring down prices … [Read more...] about Amgen Announces Major Price Cut For Its Breakthrough Cholesterol Drug

Filed Under: Innovation, Prescription Drugs

Save The Safety Net Drug Program For Patients Who Need Help

POSTED BY Grace-Marie Turner | Forbes on July 20, 2018.

A poster on the side of a bus stop in downtown Washington D.C. read: “Let 340B,” clearly a sign of an organized campaign asking Congress not to interfere with the gravy train for some hospital systems that this obscure provision has become. The safety net drug program, usually referred to as 340B for the section authorizing it in the Public Health Service Act, was created by Congress in 1992 to … [Read more...] about Save The Safety Net Drug Program For Patients Who Need Help

Filed Under: Medicaid, Prescription Drugs

A Surgical Approach To High Prescription Drug Prices

POSTED BY Grace-Marie Turner | Forbes on June 4, 2018.

President Trump’s plan to lower prescription drug costs uses a surgeon’s scalpel to address a range of issues, offering nearly 30 policy recommendations to modernize payment policies, weed out counter-productive regulations, improve price transparency, and expand competitive price negotiations. The plan reflects the complexity of the industry and the regulatory system that governs government … [Read more...] about A Surgical Approach To High Prescription Drug Prices

Filed Under: Medicare, Prescription Drugs

Drug Companies Need To Do Their Jobs

POSTED BY Grace-Marie Turner | Forbes on February 6, 2018.

President Trump emphasized during his State of the Union address his determination to fulfill a campaign promise to lower prescription drug prices. His administration already is making progress:  Food and Drugs Commissioner Scott Gottlieb is leading his agency to dramatically accelerate approval of generic drugs.  Competition in generic drugs – which make up 87% of drug consumption in the U.S. … [Read more...] about Drug Companies Need To Do Their Jobs

Filed Under: Prescription Drugs

Price Transparency Is Critical to Drug Pricing Solutions

POSTED BY Grace-Marie Turner | Forbes on July 12, 2017.

Prescription drug costs are a hot political issue, not as much because of the share of the U.S. health care dollar they consume but because consumers pay a larger share of their drug costs out of pocket than they do for other health care. The lack of price transparency for prescription drugs is a large part of the problem, and making pricing more transparent throughout the process could help in … [Read more...] about Price Transparency Is Critical to Drug Pricing Solutions

Filed Under: Prescription Drugs

Biosimilar Drugs Offer Promise For Drug Price Savings, But Risks Remain

POSTED BY Grace-Marie Turner | Forbes on June 6, 2017.

The issue of prescription drug prices continues to top the list of public concerns about health costs, and Congress and the administration are floating possible policy solutions. Solutions to this complex problem will be most effective if they are targeted and geared toward encouraging rather than undermining competition and innovation in the vibrant 21st century life sciences industry. One … [Read more...] about Biosimilar Drugs Offer Promise For Drug Price Savings, But Risks Remain

Filed Under: Health Insurance, Medicare, Prescription Drugs

More and better information can enhance patient care

POSTED BY Grace-Marie Turner on May 23, 2017.

With Congress intensely focused on big decisions involving health reform legislation, it’s easy to miss other initiatives that are quietly moving through Congress which could make a major contribution to achieving the goals of health reform One example is a measure offered by Rep. Morgan Griffith (R-VA) that would open the lines of communication between biopharmaceutical, medical device, and … [Read more...] about More and better information can enhance patient care

Filed Under: Consumer-Directed Care, Health Insurance, Prescription Drugs, Reform Initiatives

« Previous Page
Next Page »

Primary Sidebar

NEW – OF INTEREST

Health Care Choices 20/20:

A Vision for the Future


See the latest interview of Grace-Marie Turner on C-SPAN

SEARCH

Categories

  • Brian Blase
  • Consumer-Directed Care
  • Doug Badger
  • Grace-Marie Turner
  • Health Insurance
  • Health Policy Consensus Group
  • Health Savings Accounts
  • Innovation
  • Medicaid
  • Medicare
  • Newsletter
  • ObamaCare
  • Prescription Drugs
  • Published
    • Forbes
    • Fox Business
    • Health Affairs
    • LA Times
    • National Review
    • New York Post
    • RealClearHealth
    • Sun Sentinel
    • The Daily Signal
    • The Hill
    • The New York Times
    • The Wall Street Journal
    • The Washington Times
  • Reform Initiatives
  • State Issues
  • Uncategorized

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute, Inc © 2021; · Log in